EGFR and lung carcinoma: In conclusion, we have established an LMC model for EGFR-mutant lung cancer and demonstrated the potential of third generation EGFR-TKI AZD9291, on not only EGFR-TKI naïve LMC but also EGFR-TKI-refractory LMC.